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T h ed a t ac o n t a i n e di nt h eO r p h a n e t“Orphan Drugs”
database is extracted from official sources. This data
includes a list of all substances which have been granted
an orphan designation for a disease(s) considered as rare
in Europe, whether further developed to become drugs
with marketing authorisation (MA) or not. The Orpha-
net database also includes drugs without an orphan des-
ignation as long as they have been granted a MA with a
specific indication for a rare disease. Orphanet also pub-
lishes a quarterly report (“Orphanet Report Series”) list-
ing orphan drugs on the European market with or
without prior orphan designation. In order to improve
access to Orphanet’s rich database of information and
resources, the search engine has been recalibrated to
render data more accessible. In addition to existing
search options (by drug or disease), four new sub-tabs
improve the visibility of information pertaining to
orphan drugs, allowing users to search by a wider range
of criteria. Several alphabetical lists of designated pro-
ducts, orphan-designated products with MA, substances
and drug trade names are now available. New advanced
search options allow users to refine their search by
sponsor, MA holder and ATC (Anatomic, Therapeutic,
Chemical) category. Substances are now clearly sepa-
rated from trade names in the results pages: trade
names are used solely for products granted MA, whereas
substances with orphan designation status (prior to MA)
are referred to by their active molecule. Additionally,
each substance or trade name is linked to the “Clinical
trials” sub-tab of the “Research and trials” tab. Users can
retrieve clinical trial(s) that are (or have been) per-
formed for a particular drug. These can also be searched
by a wider range of criteria (disease concerned, principal
investigator by country, sponsor or clinical trial cate-
gory). These features are available in all five languages
of the Orphanet website.
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